36 commercial payer policies list J2786. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
36 policies from 18 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2786 |
|---|---|---|
| Cinqair (reslizumab) | Not recorded | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Cinqair (reslizumab)Effective 03/01/2025 - 03/31/2025 | Apr 1, 2024 | Prior auth requiredInferred from policy title |
| Cinqair (reslizumab)Effective 04/01/2025 - 03/31/2025 | Not recorded | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair)Effective 01/01/2019 - 07/31/2019 | Jan 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair)Effective 05/01/2022 - 04/30/2023 | May 1, 2022 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair)Effective 05/01/2023 - 03/31/2024 | May 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair)Effective 06/01/2021 - 04/30/2022 | Jun 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair)Effective 07/01/2020 - 05/31/2021 | Jul 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Reslizumab (Cinqair)Effective 08/01/2019 - 06/30/2020 | Aug 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2786 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Jul 1, 2026 | Covered |
| Respiratory Interleukins (Cinqair, Fasenra, & Nucala) | Jul 1, 2026 | Covered |
| Respiratory Interleukins (Cinqair, Fasenra, & Nucala) – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Respiratory Interleukins (Cinqair, Fasenra, & Nucala) – Individual Exchange Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur, Nucala) and IL-5 Receptor Antagonist (e.g., Fasenra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab | Nov 15, 2025 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab | Nov 15, 2025 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab | Nov 15, 2025 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab | Nov 15, 2025 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur, Nucala) and IL-5 Receptor Antagonist (e.g., Fasenra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Jul 1, 2026 | Covered |
| Respiratory Interleukins (Cinqair, Fasenra, & Nucala) | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab (e.g., Cinqair) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| CINQAIR (RESLIZUMAB) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab (Cinqair) | Apr 6, 2016 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Cinqair (Reslizumab) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Reslizumab (Cinqair); CP.PHAR.223 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Monoclonal Interleukin-5 Antagonists [mepolizumab (Nucala), reslizumab (Cinqair), and benralizumab (Fasenra)] | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| 00511 reslizumab (Cinqair) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Cinqair (reslizumab) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2786 |
|---|---|---|
| Respiratory Interleukins (Cinqair, Fasenra, & Nucala) | Jul 1, 2026 | Covered |